Research programme: cancer immunotherapeutics - CARsgen

Drug Profile

Research programme: cancer immunotherapeutics - CARsgen

Alternative Names: CAR-CD19 T - CARsgen; CAR-CD19 T cells - CARsgen; CD19 Redirected Autologous Cells - CARsgen; CSG-002; CSG-004; CSG-005; CSG-007; CSG-CD19

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator CARsgen
  • Class CAR-T cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Gastric cancer; Glioblastoma; Haematological malignancies; Hepatocellular carcinoma; Lung cancer; Neuroblastoma; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 13 Oct 2016 CARsgen Therapeutics and RenJi Hospital plan a phase I trial for B-cell lymphoma and B-cell leukaemia in China (IV) (NCT02933775)
  • 22 Oct 2015 CARsgen Therapeutics and Shanghai Cancer Institute enters into research and development agreement for novel autologous CAR-T cell therapies
  • 22 Oct 2015 Preclinical trials in Cancer in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top